Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

Weight-loss supplements promise quick results but often lack scientific backing. Popular ingredients like caffeine, green tea ...

While cinnamon and honey water can be tasty and beneficial additions to your diet, it’s essential to recognize that they are ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

ALL the talk right now is about weight-loss injections but I’m addicted to slimming pills, even though I know they aren’t the ...

Kathy Bates turned heads at the 2025 Golden Globes after her impressive 100-lb. weight loss. Now, the 76-year-old ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

In the ever-evolving world of weight loss supplements, AquaSculpt has emerged as a game-changer, captivating the attention of ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.